OrbiMed Advisors LLC's Form 4 filing
Upstream Bio, Inc. (UPB) · filed Oct 17, 2024
- Accession no.
- 0000947871-24-000806
- Filed
- Oct 17, 2024, 4:17 PM ET
- Trade date
- Oct 15, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 4 derivative transactions. Open-market purchases total $14.0M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | Director, 10% Owner |
| OrbiMed Israel GP II, L.P.CIK 0001682090 | Director, 10% Owner |
| OrbiMed Advisors Israel II LtdCIK 0001682093 | Director, 10% Owner |
| OrbiMed Capital GP VIII LLCCIK 0001845804 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 15, 2024 | Common Stock | CConversionAcquired | +721,956 | –F1 | – | 973,716 | Indirect | Duplicate filing |
| Oct 15, 2024 | Common Stock | PPurchaseAcquired | +165,000 | $17.00 | +$2,805,000 | 1,138,716 | Indirect | Duplicate filing |
| Oct 15, 2024 | Common Stock | CConversionAcquired | +2,887,833 | –F1 | – | 3,894,873 | Indirect | Duplicate filing |
| Oct 15, 2024 | Common Stock | PPurchaseAcquired | +660,000 | $17.00 | +$11,220,000 | 4,554,873 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 15, 2024 | Common Stock | CConversionDisposed | −524,500 | –F1 | – | 0 | Indirect | Duplicate filing |
| Oct 15, 2024 | Common Stock | CConversionDisposed | −2,098,000 | –F1 | – | 0 | Indirect | Duplicate filing |
| Oct 15, 2024 | Common Stock | CConversionDisposed | −197,456 | –F1 | – | 0 | Indirect | Duplicate filing |
| Oct 15, 2024 | Common Stock | CConversionDisposed | −789,833 | –F1 | – | 0 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
Referenced by the price of 2 transactions in Table I and 4 transactions in Table II.